“Testing for combined urinary PCA3 and TMPRSS2:ERG (T2:ERG) RNA can improve detection of prostate cancer, according to a study published online May 18 in JAMA Oncology.
“Martin G. Sanda, M.D., from the Emory University School of Medicine in Atlanta, and colleagues conducted a multicenter diagnostic evaluation and validation in academic and community-based ambulatory urology clinics. A sample of men presenting for first-time prostate biopsy without preexisting prostate cancer were enrolled: 516 in the developmental cohort and 561 in the validation cohort. Urinary PCA3 and T2:ERG RNA were measured before prostate biopsy.”
“A new study shows that men who have a specific marker present in their prostate biopsy may benefit from close follow-up and additional biopsies. When present, the marker—a protein found in the biopsied tissue—increases the chance that cancer will develop in the prostate. This could identify patients that need to be carefully monitored from those that do not, a decision that is currently difficult to make for clinicians. The study is published in the Journal of Clinical Oncology.“
A phase II clinical trial is being held to investigate the effect of an experimental drug, ABT-888, on castration-resistant prostate cancer (CRPC) in patients who have a genetic mutation known as a TMPRSS2:ERG gene fusion. In lab studies, ABT-888 used in combination with the prostate cancer drug abiraterone (Zytiga), helped shrink prostate cancer tumors and was especially effective for shrinking tumors that had the genetic mutation. The clinical trial is being led by investigators at the University of Michigan Comprehensive Cancer Center and conducted at multiple sites throughout the country. For more information about this trial, “A Randomized Gene Fusion-Stratified Phase II Trial of Abiraterone with or without ABT-888 for Patients with Metastatic Castration-Resistant Prostate Cancer,” call the U-M Cancer Answerline at 800-865-1125.